Skip to main content

New story in Health from Time: Leaked Data From a Key Remdesivir Study Suggest the Potential Coronavirus Drug Is Not Effective



A summary of a study conducted in China on a potential COVID-19 treatment, remdesivir, was posted on the World Health Organization (WHO) website on Thursday and then removed.

The researchers responsible for the study had not approved its posting; Tarik Jasarevic, a WHO spokesperson told STAT that it was “inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments.”

Remdesivir, an experimental drug originally developed to treat Ebola, is not yet approved for that or any other disease. But studies conducted by remdesivir’s maker, Gilead, have shown that the experimental drug could be effective against coronaviruses like those that cause SARS and MERS. So during the COVID-19 crisis, Chinese researchers contacted the company about using it to treat the sickest patients, and Gilead made the drug available under a compassionate use program, to treat those with no other treatment options.

After Gilead agreed, Chinese doctors launched two formal studies of remdesivir; one in severely ill patients, and another in people with milder disease. Both studies compared the drug to a placebo. But in mid-April, both were suspended when scientists could not enroll the more than 400 patients needed for each trial.

The summary posted temporarily to the WHO’s website involved the trial to treat severe patients. The Chinese researchers noted that remdesivir was “not associated with a difference in time to clinical improvement,” according to STAT, which took a screen shot of the study before it was removed. In addition, according to the documentation briefly published on the WHO site, after a month, there was almost no difference in the fatality rate of patients given remdesivir compared to those who received the placebo.

In a statement responding to the results, Dr. Merdad Parsey, chief medical officer of Gilead Sciences, said “we believe the post included inappropriate characterizations of the study. The study was terminated early due to low enrollment and, as a result, it was underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in the disease.”

Parsey seemingly was referencing recent remdesivir studies involving COVID-19 patients in the U.S., Europe and Canada, which have hinted at more positive results. In one, which involved 53 patients who were treated with remdesivir on a compassionate use basis, 68% of those experiencing severe respiratory symptoms improved after 10 days. In another, involving 125 U.S. patients, most who took the drug improved enough to be discharged from the hospital. However, unlike the Chinese studies, those trials did not compare remdesivir to a placebo.

The studies from China would be the first to provide solid data from gold standard clinical trials that randomly assigned people to remdesivir or placebo. Their results would likely guide decisions about ongoing trials in the U.S. and around the world, including one sponsored by Gilead and another by the National Institutes of Health, seeking to uncover which COVID-19 patients might benefit most from the drug, and when in the course of the disease the drug is most effective. Those studies, however, will take months to complete, regardless of this data leak.

Labels:

Popular posts from this blog

New story in Health from Time: COVID-19 Has Been ‘Apocalyptic’ for Public Transit. Will Congress Offer More Help?

While trying to get to work over the past few months, Brittany Williams, a Seattle home care worker, has often been passed by two or three buses before one stops to let her board. Buses in her area that once carried anywhere from about 50 to 100 passengers have been limited to between 12 and 18 to prevent overcrowding in response to coronavirus, and Williams’ commute, typically a half-hour ride, now takes more than double that time. Other Seattle transit riders have described budgeting as much as an extra hour per trip to account for the reduced capacity, eating into their time at work, school or with family. Even with the ridership limits in place, Williams, 34, doesn’t feel safe on public transit. Some passengers don’t wear face coverings, and bus drivers sometimes ignore capacity limits, she says. On one ride with her seven-year-old son, she decided to get off at a stop far from her home after a driver allowed a crowd of people to board. “It’s very trying. I’ll put...
Read more

New video by blogilates on YouTube

Day 8 - 14 | Blogilates 2020 Challenge You guys are CRUSHING the #2020Challenge so far! Idk about you but my abs are soooooore! This week, we're doing 20 reps of abs every day + 20 reps of another new exercise every day! If you need a little extra motivation, text my number (510-692-4556) and tell me all about it so we can come up with a solution together! This link also works: https://ift.tt/2Qjqw7G This week's moves are: Jan. 8th (starts 0:48) - 20 butterfly bridges + 20 criss cross (butt + abs) Jan. 9th (starts 2:43) - 20 oil riggers + 20 rollovers (arms + abs) Jan. 10th (starts 8:29) - 20 lunges + 20 leg outs (legs + abs) Jan. 11th (starts 11:03) - 20 walnut crushers + 20 single leg drops (back + abs) Jan. 12th (starts 13:41) - 20 sprinters + 20 crunches (obliques + abs) Jan. 13th (starts 16:27) - 20 squat jumps + 20 russian twists (cardio + abs) Jan. 14th (starts 18:57) - 20 plank jacks + 20 butt ups (total body + abs) Here is where I get all of my music! Epidemic Sound: ...
Read more

New story in Health from Time: 265 Million People Could Face Hunger in ‘Unprecedented’ Crisis, World Food Program Expert Warns

The world faces an “unprecedented” food crisis due to the COVID-19 pandemic, which has caused both severe job losses and major disruptions in food supply chains, the U.N. World Food Programme’s Chief Economist warns. “When you have these severe job losses, or you have big lockdowns, that means that those people become vulnerable,” Arif Husain tells TIME. An estimated 265 million people could go hungry in 2020, nearly double the 2019 figures, according to WFP’s projection in April. As millions around the world are losing their jobs or seeing their incomes cut , it’s increasingly difficult for them to afford food, Husain says. At the same time, lockdown measures and trade restrictions are making it harder to transport food from where it’s produced to where it’s needed, resulting in food going to waste in the field. Refugees and people in conflict zones like Yemen, Syria, and Burkina Faso and those already living hand-to-mouth prior to the coronavirus outbreak are parti...
Read more